

**Ethics and IRB Considerations** 



### What are psychedelic drugs?

- A group of substances that change or enhance sensory perceptions, thought processes, and energy levels
- Sometimes called hallucinogens
- Schedule I Controlled Substances/No currently accepted medical use in the U.S.
- "Classic" psychedelics: LSD and psilocybin
- "Empathogens" MDMA (ecstasy)

#### **Brief Timeline**

- LSD synthesized by Albert Hofmann in 1938
- Psychedelic research was popular in the 1950's
- Early 1960's The FDA designated LSD as an experimental agent
- Late 1960's LSD increasingly became viewed as a drug of abuse and outlawed in 1968
- 1990's renewed interest in potential therapeutic benefits
- 2000 Johns Hopkins researchers obtain regulatory approval to resume psychedelic research
- June 2023 FDA issues draft guidance for psychedelic research

### Some areas of study using psychedelics:

- Smoking cessation
- Major depression disorder
- Alzheimer's Disease (examining impact on depression in MCI and early dementia)
- Anorexia Nervosa
- Cancer-related anxiety and depression
- Alcohol dependence
- PTSD



## **IRB** Considerations

- Careful screening
  - Exclude those with cardiovascular risk
  - Exclude those at risk for psychosis
  - Exclude contraindicated medications
- Careful preparation
  - Minimum 6-8 hours of rapport building
  - Unstructured counseling for patients
- · Close monitoring during acute effects
  - Sessions typically last 6-8 hours
  - Non-directive, non-judgmental presence
- Aftercare / integration
  - Days and weeks after drug administration
  - Unstructured counseling for patients





Johnson et al., J Psychopharmacol 2008; 22(6):603-620



## **IRB** Considerations

- Respect for Persons

  - Informed consent challenges
    Vulnerability given society hype
    Vulnerability during acute drug effects
- Beneficence
  - Are study teams adequately trained?
  - Are risks adequately understood by study team AND HRP staff?
- Justice
  - Are SOC/TAU enough?

  - Is the disease burden currently well-managed?
    Is there adequate representation in the current literature?



Frederick S. Barrett, Ph.D., Johns Hopkins University School of Medicine, 2023 AAHRPP Conference

SOC = Standard of Care; TAU = Treatment as Usual

# Steps for the Investigator

#### 1) Obtain IRB Approval

- a) Review and approve using usual criteria for approval
- b) Approve with contingencies pending approval from additional agencies.
- 2) Submit to the Research Advisory Panel (RAP) of California for review and approval (<a href="https://oag.ca.gov/research/guide">https://oag.ca.gov/research/guide</a>)
  - Required by CA law for studies using Schedule I and Schedule II Controlled Substances as the main study drug
  - b) RAP evaluates the scientific validity of each proposed project
  - c) May reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research
  - d) Researchers should obtain IRB and FDA approval of their study BEFORE submitting the study for review by the Research Advisory Panel of California.

#### 3) Submit a Form 225 to the DEA to obtain DEA approval (<a href="https://deadiversion.usdoj.gov/">https://deadiversion.usdoj.gov/</a>)

- a) The study must comply with Drug Enforcement Administration (DEA) regulations for research, manufacturing, handling, storage
- b) DEA authorization is required to conduct each specific protocol

# Resources

FDA Draft Guidance: Psychedelic Drugs: Considerations for Clinical Investigations, June 2023 <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations</a>

U.S. Department of Justice Drug Enforcement Administration, Diversion Control Division <a href="https://www.deadiversion.usdoj.gov/index.html">https://www.deadiversion.usdoj.gov/index.html</a>

State of California Department of Justice, Research Advisory Panel <a href="https://oag.ca.gov/research">https://oag.ca.gov/research</a>

USC Environmental Health & Safety, DEA Registration and Renewal <a href="https://ehs.usc.edu/research/cspc/dea/#schedule4">https://ehs.usc.edu/research/cspc/dea/#schedule4</a>

USC HRPP – California Research Laws

https://hrpp.usc.edu/policies/california-research-laws/